Table 2 Comparative demographics according to tumoral expression of IL8
From: Surgical peritoneal stress creates a pro-metastatic niche promoting resistance to apoptosis via IL-8
Study population (n = 32) | High IL8 group (n = 8) | Low IL8 group (n = 24) | p-value | |
|---|---|---|---|---|
Age (years) | 62.4 (± 10.1) | 61.4 (± 12.6) | 62.8 (± 9.4) | 0.75 |
BMI | 23.7 (± 3.9) | 24.4 (± 4.5) | 23.7 (± 3.9) | 0.68 |
CA 125 (U/ml) at baseline | 1878.5 (± 2402.6) | 3615.6 (± 4010.7) | 1299.6 (± 1218.2) | 0.01* |
Histological type | ||||
Serous | 81.3% (n = 26) | 87.5% (n = 7) | 79.2% (n = 19) | 0.67 |
Mucinous | 3.1% (n = 1) | 0 | 4.2% (n = 1) | |
Endometrioid | 6.2% (n = 2) | 0 | 8.3% (n = 2) | |
Undifferentiated | 9.4% (n = 3) | 12.5% (n = 1) | 8.3% (n = 2) | |
FIGO stage | ||||
IIIC | 87.5% (n = 28) | 75.0% (n = 6) | 91.7% (n = 22) | 0.08 |
IV | 12.5% (n = 4) | 25.0% (n = 2) | 8.3% (n = 2) | |
Number of NAC courses | 4 (3–7) | 4 (3–6) | 4 (3–7) | 0.32 |
Total number of chemotherapy courses | 6 (3–12) | 6 (3–10) | 6 (3–12) | 0.24 |
Delay between diagnosis and surgery (months) | 3.7 (2.6–9.3) | 3.8 (2.9–7.0) | 3.7 (2.6–9.3) | 0.42 |
Completeness of cytoreduction scorea | ||||
CC-0 | 78.1% (n = 25) | 62.5% (n = 5) | 83.3% (n = 20) | 0.22 |
CC-1 | 3.1% (n = 1) | 0 | 4.2% (n = 1) | |
CC-2 | 12.5% (n = 4) | 25.0% (n = 2) | 8.3% (n = 2) | |
CC-3 | 6.3% (n = 2) | 12.5% (n = 1) | 4.2% (n = 1) | |
Duration of surgical procedure (min) | 389 (± 127) | 360 (± 132) | 401 (± 127) | 0.52 |
Disease free survival (months) | 29.4 (± 5.1) | 12.2 (± 1.0) | 35.6 (± 6.5) | 0.001** |
Overall survival (months) | 54.8 (± 6.1) | 32.4 (± 7.3) | 63.3 (± 7.1) | 0.009** |
Chemoresistance | ||||
Yes | 57.2% (n = 16) | 100.0% (n = 8) | 40.0% (n = 8) | 0.004** |
No | 42.8% (n = 12) | 0 | 60.0% (n = 12) | |